Organisation paid for research Program year 2025 Source: CMS Open Payments

Brain Matters Research Inc

Neither a doctor nor a teaching hospital

Research payments

$1,652,992

150 payments

Through program year 2025, Brain Matters Research Inc is reported as receiving $1,652,992 in research payments, across 150 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $20,757 9
2024 Research $44,461 7
2023 Research $107,826 11
2022 Research $104,144 8
2021 Research $190,187 29
2020 Research $414,328 38
2019 Research $771,290 48

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $810,654 80 payments
  2. Genentech, Inc. $664,658 61 payments
  3. F. Hoffmann-La Roche AG $171,281 7 payments
  4. Novartis Pharmaceuticals Corporation $5,500 1 payment
  5. Avid Radiopharmaceuticals, Inc. $900 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Phase II Study of Anti Tau in Prodromal to Mild Ad $664,658 61 payments
  2. Anti-Amyloid Treatment in Asymptomatic Alzheimers Disease -A4 Study $383,396 12 payments
  3. PH Ib Crenezumab Eff Sfy Mild Mod Ad $171,281 7 payments
  4. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $120,447 7 payments
  5. Anti-Amyloid Treatment in Asymptomatic Alzheimers Disease -A4 Study $44,577 3 payments
  6. A Single- and Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of Ly3002813 in Patients With Mild Cognitive Impairment Due to Alzheimers Disease Or Mild to Moderate Alzheimers Disease Or Mild to Moderate Alzheimers Disease $41,675 3 payments
  7. A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of Ly3314814 in Mild Alzheimers Disease Dementia $41,336 1 payment
  8. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $35,961 3 payments
  9. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $26,970 2 payments
  10. Assessment of Safety Tolerability and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $25,218 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record